InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...
Jounce Therapeutics is a clinical stage immunot...
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into ...
Sangamo Therapeutics, Inc. is focused on transl...
Premier operates one of the nationâs largest performance improvement alliances o...
Premier operates one of the nationâs largest ...
Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...
Reata is a clinical-stage biopharmaceutical com...
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in ...
CNS Pharmaceuticals is a pre-clinical stage bio...
We are a clinical stage biopharmaceutical company focused on the discovery, develo...
We are a clinical stage biopharmaceutical compa...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Join the National Investor Network and get the latest information with your interests in mind.